HK Stock Market Move | EVEREST MED (01952) Rises Nearly 5% in Early Trading; XINGBITUO Makes Its Debut at the National Cardiovascular Academic Conference

EVEREST MED (01952) rose nearly 5% in early trading. As of press time, it was up 3.71% at HK$29.6, with a turnover of HK$68.155 million. On the news front, during the 37th Great Wall International Congress of Cardiology & Asian Heart Society 2026 (GW-ICC/AHS.26), XINGBITUO (etripamil nasal spray) made its debut at the National Cardiovascular Academic Conference. The "PSVT Diagnosis and Treatment Model Innovation and Full-Course Management Academic Seminar" was held concurrently, gathering experts in the field of arrhythmia to exchange views on the acute episode management of paroxysmal supraventricular tachycardia (PSVT), clinical evidence for innovative treatments, and full-course management pathways. Public information shows that in September this year, EVEREST MED announced that the National Medical Products Administration of China has approved the new drug marketing application for XINGBITUO (etripamil nasal spray) for the treatment of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) in adults and conversion to sinus rhythm, providing Chinese PSVT patients with a new out-of-hospital treatment option for acute episodes.